Expression in a Recombinant Murid Herpesvirus 4 Reveals the In Vivo Transforming Potential of the K1 Open Reading Frame of Kaposi's Sarcoma-Associated Herpesvirus by Douglas, J et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression in a Recombinant Murid Herpesvirus 4 Reveals the In
Vivo Transforming Potential of the K1 Open Reading Frame of
Kaposi's Sarcoma-Associated Herpesvirus
Citation for published version:
Douglas, J, Dutia, B, Rhind, S, Stewart, JP & Talbot, SJ 2004, 'Expression in a Recombinant Murid
Herpesvirus 4 Reveals the In Vivo Transforming Potential of the K1 Open Reading Frame of Kaposi's
Sarcoma-Associated Herpesvirus' Journal of Virology, vol. 78, no. 16, pp. 8878-8884. DOI:
10.1128/JVI.78.16.8878-8884.2004
Digital Object Identifier (DOI):
10.1128/JVI.78.16.8878-8884.2004
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Virology
Publisher Rights Statement:
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
JOURNAL OF VIROLOGY, Aug. 2004, p. 8878–8884 Vol. 78, No. 16
0022-538X/04/$08.000 DOI: 10.1128/JVI.78.16.8878–8884.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Expression in a Recombinant Murid Herpesvirus 4 Reveals the In
Vivo Transforming Potential of the K1 Open Reading Frame
of Kaposi’s Sarcoma-Associated Herpesvirus
Jill Douglas,1 Bernadette Dutia,1 Susan Rhind,2 James P. Stewart,3 and Simon J. Talbot1*
Centre for Infectious Diseases1 and Department of Veterinary Pathology,2 University of Edinburgh, Edinburgh, and
Department of Medical Microbiology, University of Liverpool, Liverpool,3 United Kingdom
Received 19 January 2004/Accepted 2 April 2004
Murid herpesvirus 4 (commonly called MHV-68) is closely related to Kaposi’s sarcoma-associated herpes-
virus (KSHV) and provides an excellent model system for investigating gammaherpesvirus-associated patho-
genesis. MHV-76 is a naturally occurring deletion mutant of MHV-68 that lacks 9,538 bp of the left end of the
unique portion of the genome encoding nonessential pathogenesis-related genes. The KSHV K1 protein has
been shown to transform rodent fibroblasts in vitro and common marmoset T lymphocytes in vivo. Using
homologous recombination techniques, we successfully generated recombinants of MHV-76 that encode green
fluorescent protein (MHV76-GFP) and KSHV K1 (MHV76-K1). The replication of MHV76-GFP and MHV76-
K1 in cell culture was identical to that of MHV-76. However, infection of BALB/c mice via the intranasal route
revealed that MHV76-K1 replicated to a 10-fold higher titer than MHV76-GFP in the lungs at day 5 postin-
fection (p.i.). We observed type 2 pneumocyte proliferation in areas of consolidation and interstitial inflam-
mation of mice infected with MHV76-K1 at day 10 p.i. MHV76-K1 established a 2- to 3-fold higher latent viral
load than MHV76-GFP in the spleens of infected mice on days 10 and 14 p.i., although this was 10-fold lower
than that established by wild-type MHV-76. A salivary gland tumor was present in one of four mice infected
with MHV76-K1, as well as an increased inflammatory response in the lungs at day 120 p.i. compared with that
of mice infected with MHV-76 and MHV76-GFP.
Murid herpesvirus 4 (commonly called MHV-68) infection
of laboratory mice provides an excellent system for the study of
gammaherpesvirus pathogenesis (2, 7, 19, 23, 24, 33). After
intranasal infection of mice, MHV-68 replicates initially in the
lungs (27). This infection is cleared by days 10 to 14 postinfec-
tion (p.i.) by CD8 T cells (8), although the virus persists in a
latent form in epithelial cells at this site (25). MHV-68 spreads
to the spleen, where it infects B lymphocytes, macrophages,
and dendritic cells (9, 28, 30, 34), causing splenomegaly driven
by CD4 T cells (29). Life-long virus persistence occurs pre-
dominantly in surface immunoglobulin D-negative B cells after
the resolution of splenomegaly (35).
MHV-76 was isolated from the yellow-necked mouse
(Apodemus flavicollis) in Slovakia and was recently shown by
genome sequencing to be identical to MHV-68 except for a
9,538-bp deletion at the left end of the unique region (17). This
deletion is nonessential, encompassing four protein-coding
genes (M1, M2, M3, and M4) and eight viral tRNA-like genes,
none of which are found in other gammaherpesviruses. The
roles of M1, M4, and the viral tRNAs during MHV-68 infection
are currently unknown. M2 is expressed in B cells during la-
tency (18). Although it is nonessential for the development of
latency, M2 is responsible for much of the MHV-68-induced
peak of viral latency in the spleen during splenomegaly (11,
18), and the M2 protein is a target for the host immune re-
sponse (10). M3 encodes a secreted chemokine binding protein
that is expressed during both acute infections and the persis-
tence of MHV-68 in mice (21, 31). Although the replication of
MHV-76 is identical to that of MHV-68 in cell culture, after
infections of mice MHV-76 is cleared more rapidly from the
lungs (17). This is probably due to an enhanced inflammatory
response in the lungs against MHV-76. Splenomegaly is also
significantly reduced after MHV-76 infection, consistent with a
much reduced latent viral load in the spleen (17).
Since the start of the AIDS pandemic, Kaposi’s sarcoma
(KS) has become one of the most prevalent tumors in men
under 60 years old (1). Long before AIDS, KS was thought to
be caused by an infectious agent. The large relative risk of KS
among certain categories of AIDS patients and the clustering
of KS in different populations have strengthened this view.
DNA sequences from a novel gammaherpesvirus, termed KS-
associated herpesvirus (KSHV), were identified in an AIDS-
associated KS biopsy (5). KSHV has since been found in all
epidemiological forms of KS and also in primary effusion lym-
phomas (4). This new herpesvirus is related to an oncogenic
herpesvirus from monkeys (herpesvirus saimiri [HVS]) and to
a well-characterized human herpesvirus (Epstein-Barr virus)
which is associated with several human cancers (20, 22).
At a position equivalent to that of the main transforming
proteins of HVS (saimiri transforming protein [STP]) and Ep-
stein-Barr virus (latent membrane protein 1), KSHV contains
a distinct open reading frame (ORF) called K1 (12). K1 is a
46-kDa transmembrane glycoprotein (12). While the amino-
terminal extracellular domain of K1 is extremely variable be-
tween isolates of KSHV, the carboxy-terminal short cytoplas-
mic tail is relatively well conserved (36). This carboxy-terminal
cytoplasmic tail contains a functional immunoreceptor ty-
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rosine-based activation motif (ITAM) (15). The ITAM is ca-
pable of transducing signals to induce cellular activation, cal-
cium mobilization, and tyrosine phosphorylation, which are all
indicative of lymphocyte activation (14, 15). However, unlike
other ITAM-based signal transduction events that require a
ligand-receptor interaction, K1 signaling appears to occur con-
stitutively (14). The K1 protein has been shown to interact with
several cellular signal transduction proteins, including Vav,
p85, and Syk kinase (15), and to induce the activity of nuclear
factor of activated T cells (14). ITAM-dependent signaling by
K1 has been shown to augment the lytic replication of KSHV
in B cells (13). In addition to the transformation of rodent
fibroblasts, K1 can also functionally replace STP in HVS for
the immortalization of common marmoset T lymphocytes to
interleukin-2-independent growth and for the induction of
lymphomas in common marmosets (16). Prakash et al. (21a)
produced transgenic mice expressing K1 under the control of a
simian virus 40 (SV40) promoter. These mice showed en-
hanced NF-B activity in nonmalignant lymphocytes and tu-
mors in 2 of 13 14-month-old mice. One of these tumors was a
plasmoblastic malignant lymphoma and the other was a spin-
dle-cell sarcomatoid tumor (21a).
The aim of this study was to ascertain the function of the
KSHV K1 protein in vivo. There is no amenable animal model
system for KSHV. While MHV-68 has been informative about
aspects of gammaherpesvirus biology, it does not contain an
equivalent of K1 (32). To assess the function of K1 in vivo, we
therefore adopted the approach of generating an MHV-68
recombinant containing K1. We surmised that MHV-76 was
the best vector to use for this since it is missing several patho-
genesis-related genes (17). There was therefore less chance of
the biological effects of K1 being masked by a duplicate
MHV-68 function. We successfully generated two recombi-
nants of MHV-76 that encode green fluorescent protein (GFP)
and KSHV K1. The pathogenesis of these recombinant viruses
in the context of infection of BALB/c mice was investigated.
MATERIALS AND METHODS
Cell lines and viruses. MHV-76 and recombinant viruses were grown and
titrated on BHK-21 cells (in Glasgow’s medium supplemented with 10% [vol/vol]
newborn calf serum, 10% [vol/vol] tryptose phosphate buffer, penicillin [60 g/
ml], streptomycin [100 g/ml], and 2 mM glutamine) as described previously.
MHV-76 was originally isolated during field studies from the yellow-necked
mouse, A. flavicollus (3). It was subsequently plaque purified on BHK-21 cells
and characterized as described previously (17).
Plasmid construction. KSHV ORF K1 was amplified from BCP1 DNA with
the oligonucleotides KLA (GTACGAGCTCGCTAGCAAGATGTTCCTGTA
TGTTGTCTG) and KLB (GTACGCGGCCGCGGTACCAATCCACTGGTT
GCG) and Advantage cDNA polymerase (BD Clontech). The PCR product was
cloned into the SacI and NotI sites of pBluescript KS-Myc (has a Myc epitope tag
between the NotI and XbaI sites of pBluescript KS). The K1-Myc sequence was
then subcloned into the SacI and KpnI sites of pUC18. The encephalomyocar-
ditis virus (EMCV) internal ribosome entry sequence (IRES) (from pBVIRE
SEGFP) was inserted at the EcoRI and SacI sites upstream of K1-Myc. The
IRES-K1Myc sequence was inserted into the SalI and XmaI 3 multiple cloning
site of pHygEGFP (BD Clontech). BglII linkers (NEB) were then added at the
BsaBI site and a BglII fragment (CMV-HygEGFP-IRES-K1Myc-POLYA) was
then cloned into the BamHI site of pBS76LHE (contains nucleotides 9539 to
12569 of MHV-68). An enhanced GFP (EGFP) control plasmid was constructed
by inserting the CMV-HygEGFP-IRES-POLYA sequence into the BamHI site
of pBS76LHE.
Construction of recombinant viruses. All recombinant virus work was per-
formed at the University of Edinburgh under United Kingdom Advisory Com-
mittee on Genetic Modification safety level 2 conditions and with notification of
the work to the Health and Safety Executive. MHV-76 genomic DNA was
prepared from purified virions as described previously (17). MHV-76 DNA (5
g) and 10 g of linearized plasmid were transfected by electroporation into 2
106 BHK-21 cells by using a double-pulse setting (high-voltage setting  600 V,
25 F, 99; low-voltage setting 260 V, 1,500 F, 329; 0.1-s interpulse delay)
on an EasyJect electroporator (EquiBio). Electroporated cells were cultured in
a six-well plate. Green fluorescent plaques were picked after 5 days and subjected
to four rounds of plaque purification by limiting dilution (in 96-well plates) with
hygromycin selection (100 g/ml). Each round of purification was verified by a
PCR to amplify MHV-76 ORF74 and K1 or EGFP. A Southern blot analysis was
performed to ensure that the recombinant viruses were free from contamination
with wild-type MHV-76. The Southern blots were probed with a 1-kb BamHI-
XmaI fragment of pBS-76LHE and a 1-kb SacII-XmaI fragment of pHygEGFP
(Fig. 1 and 2).
In vitro infections. In vitro one-step growth curves were obtained by infecting
subconfluent BHK-21 cells at a multiplicity of infection of 5 and allowing the
virus to adsorb for 1 h at 37°C. The cells were then washed three times to remove
unbound virus, and fresh medium was added. At various times p.i., the cells were
harvested by scraping into the medium. Viruses were released from the cells by
three freeze-thaw cycles, and infectious virus was quantified by a plaque assay.
All experiments were performed in duplicate.
Infection of mice and analysis of tissues. All animal experiments were per-
formed at the University of Edinburgh under United Kingdom Home Office
License number 60/2429. Female BALB/c mice were obtained from Harlan Olac
and were infected when they were 3 to 4 weeks old. Mice were anesthetized with
FIG. 1. Schematic diagram of plasmid used to generate recombi-
nant MHV76-K1 virus. The expression cassette consists of the
CMV-IE promoter and the EGFP-Hygr gene from pEGFPHyg (Clon-
tech), followed by the IRES element from EMCV. Cloned immedi-
ately downstream from the IRES is the KSHV K1 ORF followed by
the SV40 poly(A) signal (pA). These elements were cloned into a
BamHI site next to the MHV-76 genomic DNA (nucleotides 9539 to
12569 of MHV-68) in pBluescript (Stratagene). The MHV76-GFP
virus was generated by using an identical plasmid lacking the KSHV
K1 gene. The positions of the probes used for Southern hybridization
(BamHI-XmaI and SacII-XmaI) and the restriction sites for NheI and
MfeI are indicated.
FIG. 2. Southern blot showing purified MHV76-K1 recombinant
virus compared with parental MHV-76. The left panel shows MHV-76
and MHV76-K1 digested with MfeI and probed with the BamHI-
XmaI probe (Fig. 1). The right panel shows MHV-76 and MHV76-K1
digested with NheI and probed with the SacII-XmaI probe (Fig. 1).
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halothane and infected intranasally with 4  105 PFU of virus in 40 l of sterile
phosphate-buffered saline (PBS). At various times p.i., mice were sacrificed by
CO2 asphyxiation and tissues were harvested for analysis. Infectious virus was
detected by a plaque assay, and an infective-center assay was used to detect latent
virus as described previously (28).
The expression of KSHV K1 was detected by immunoprecipitation and West-
ern blotting. Tissue samples from MHV76-K1- and MHV76-GFP-infected mice
were disrupted by Dounce homogenization in RIPA buffer (PBS, 1% [vol/vol]
Nonidet P-40, 0.5% [wt/vol] sodium deoxycholate, 0.1% [wt/vol] sodium dodecyl
sulfate). The cell lysate was immunoprecipitated with a mouse monoclonal an-
tibody (9E10) recognizing the Myc epitope tag (Santa Cruz Biotechnology).
Precipitated proteins were separated in a sodium dodecyl sulfate–12% (wt/vol)
polyacrylamide gel and transferred to a nitrocellulose membrane. The Western
blot was probed with a biotin-conjugated anti-Myc-tag monoclonal antibody
(Santa Cruz Biotechnology) and streptavidin-conjugated alkaline phosphatase
(Sigma). The blot was developed with 4-nitroblue tetrazolium chloride–5-bromo-
4-chloro-3-indolylphosphate (NBT/BCIP) (Roche).
Histopathology. Mice were sacrificed by CO2 asphyxiation. Lungs were per-
fused in situ via the trachea with 10% neutral buffered Formol saline and then
processed into paraffin-embedded sections. Five-micrometer-thick sections were
cut and stained with hematoxylin and eosin for examination by light microscopy.
Immunohistochemistry. Frozen sections were fixed on slides in 4% (wt/vol)
paraformaldehyde for 1 h, washed in PBS for 5 min, and blocked for 30 min
(PBS, 1% [wt/vol] bovine serum albumin, 0.1% [vol/vol] Triton, 0.1% [wt/vol]
sodium azide, and 5% [vol/vol] normal goat serum). The primary antibody was a
rabbit polyclonal anti-MHV-68 antibody used at 1:500 for 2 h. The slides were
washed twice in PBS for 5 min each time. The secondary antibody was either goat
anti-rabbit–tetramethyl rhodamine isocyanate used at 1:400 or goat anti-rabbit–
Alexa Fluor 594 used at 1:200 for 30 min. The slides were washed twice in PBS
for 5 min each time before being mounted with fluorescent mounting medium
(Dako). All antibody incubations were carried out in a humidified chamber at
room temperature.
For cytokeratin immunohistochemistry, sections of fixed tissue were cut onto
Biobond (British Biocell Ltd.)-coated microscope slides. Sections were dewaxed
and rehydrated, and endogenous peroxidase activity was blocked with 3% (vol/
vol) hydrogen peroxide in distilled water for 10 min. The slides were washed in
PBS, and antigen retrieval was performed by incubating the slides in distilled
water containing 0.1% trypsin and 0.1% calcium (pH 7.8) for 30 min at 37°C. The
slides were washed in PBS and then incubated with an anti-cytokeratin antibody
for 1 h at room temperature (mouse monoclonal NCL-L-Pan-CK diluted 1:100;
Novocastra Laboratories). The detection of bound antibody was done by the use
of a commercially available kit (M.O.M. peroxidase kit; Vector Laboratories)
and visualization was performed with 3,3-diaminobenzidine tetrahydrochloride
(DAB) (Vector Laboratories).
Statistical analysis. Data were analyzed with GraphPad Prism software (San
Diego, Calif.). In all cases, a two-way analysis of variance with Bonferroni’s
posttest was used.
RESULTS
Generation of MHV-76 recombinants expressing EGFP and
K1. Two recombinant MHV-76 viruses were produced by ho-
mologous recombination in BHK cells. The region chosen for
insertion was the left end of the unique portion of the genome.
This is the region in which MHV-76 has a deletion relative to
MHV-68 and was therefore the region least likely to cause a
disruption of viral function (17). The first virus (MHV76-GFP)
encoded an EGFP-hygromycin resistance (EGFP-Hygr) gene
expressed from the cytomegalovirus immediate-early promoter
(CMV-IE). The IRES from EMCV was inserted downstream
of the EGFP-Hygr gene, followed by the SV40 polyadenylation
signal. The second virus (MHV76-K1) included the coding
sequence of the KSHV K1 gene inserted downstream of the
EMCV IRES. The vectors used are illustrated in Fig. 1. Re-
combinant viruses were purified by plaque purification and
limiting dilution on BHK cells. Once a pure population of
green fluorescent plaques was obtained, the genomic structure
was checked by Southern blotting. These data (Fig. 2) showed
that the MHV76-K1 virus had the insert in the predicted po-
sition on the MHV-76 genome and that there were no DNA
rearrangements. The multiple high-molecular-weight bands
observed in the MHV-76 lane probed with the Bam-Xma
probe were due to variability in the numbers of terminal re-
peats.
In vitro growth curve. The growth kinetics of MHV76-GFP
and MHV76-K1 were compared with those of wild-type
MHV-76 in an in vitro one-step growth curve. BHK cells were
infected at a multiplicity of infection of five; viruses were har-
vested over a period of 72 h and titrated. As shown in Fig. 3,
the growth kinetics of MHV76-GFP and MHV76-K1 were not
significantly different from those of MHV-76, reaching maxi-
mal titers at about 60 h p.i.
In vivo infection of mice. Groups of 20 BALB/c mice were
infected intranasally with 4  105 PFU of MHV-76, MHV76-
GFP, or MHV76-K1. The virus titers in the lungs were deter-
mined at various times p.i. by plaque assays for groups of four
mice. The data in Fig. 4A show that the titers of MHV-76 and
MHV76-K1 reached a similar level on day 5 p.i. but that the
MHV76-GFP recombinant produced significantly lower infec-
tious virus titers (P  0.01). In all three cases, virus was effec-
tively cleared from the lungs by day 10 p.i.
To examine the extent of splenomegaly after infection, we
determined the total numbers of splenocytes in mice infected
with MHV76-K1 and MHV76-GFP. As determined previously,
infection with MHV-76 does not induce a significant increase
in splenocyte numbers compared with infection by MHV-68 (6,
17). This was also shown to be the case for mice infected with
MHV76-GFP (Fig. 4B). However, we observed an increase in
the numbers of splenocytes in mice infected with MHV76-K1
on days 10 and 14 p.i. compared with those in mice infected
with either MHV76-GFP or MHV-76. This difference was sig-
nificant (P  0.05) on day 14 p.i.
To investigate the ability of MHV76-GFP and MHV76-K1
to establish latency in vivo, we determined the latent virus load
in the spleen by using an infective-center assay. The data in
Fig. 4C show that infective centers peaked around day 10 for
all three viruses but that the numbers of cells that were latently
infected with MHV76-GFP and MHV76-K1 were significantly
smaller than those of cells that were latently infected with
MHV-76. This indicates that both MHV76-K1 and MHV76-
FIG. 3. In vitro single-step growth curves of MHV-76 (),
MHV76-GFP (‚), and MHV76-K1 (E) on BHK-21 cells at a multi-
plicity of infection of 5. Data are shown as mean log10 virus titers 	
standard errors and are representative of two separate experiments,
with each performed in duplicate.
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GFP are able to establish latency in the spleen cell population,
but at much reduced levels compared to MHV-76. We noted
that although the levels were low, the numbers of latently
MHV76-K1-infected cells were two- to threefold higher than
those of latently MHV76-GFP-infected cells on days 10 and
14 p.i. This difference was found to be significant (P  0.001)
on day 10 p.i.
Pathology. The lungs of mice were examined on days 5 and
10 p.i. for histopathological changes associated with virus in-
fection. At day 5 p.i., all viruses produced a significant inflam-
matory response in the lungs, as shown by perivascular inflam-
matory cell infiltrates (dominated by lymphocytes) and edema
(Fig. 5A), which persisted until day 10 p.i. with the develop-
ment of an associated proliferative response (Fig. 5B). These
data are consistent with those observed previously for MHV-76
infections and are in contrast with the limited inflammatory
response seen at day 5 p.i. in the lungs of MHV-68-infected
mice.
The immunohistochemical detection of cytokeratin was used
to confirm type 2 pneumocyte proliferation in the lungs (Fig.
5B). At day 5 p.i., occasional areas of type 2 pneumocyte
proliferation were present in MHV76-K1-infected mice. At
day 10 p.i., strong staining of type 2 pneumocytes in chronic
proliferative inflammatory foci in MHV-76- and MHV76-K1-
infected mice was identified (Fig. 5B), but this change was
more severe for MHV76-K1-infected mice. These data confirm
the presence of epithelial hyperproliferation in association
with inflammation.
The lungs of MHV-76-, MHV76-GFP-, and MHV76-K1-
infected mice were also examined for the expression of GFP
and immunostained for MHV-76 antigens at days 5 and 10 p.i.
On day 5 p.i., the expression of GFP was clearly visible as foci
of viral infection in the lungs of MHV76-K1-infected mice
(Fig. 5C). Similarly, GFP expression was observed for MHV76-
GFP-infected mice, but it was not observed for MHV-76-in-
fected mice (data not shown). We noted that GFP expression
was not observed in all foci of viral replication and that GFP
expression was limited to cells that did not express the late viral
antigens to which the antisera were directed. This may be due
to the silencing of the CMV-IE promoter during productive
viral replication. On day 10 p.i., there was no detectable GFP
or viral antigen expression in any of the lung samples exam-
ined, consistent with the clearance of viral infection from the
lungs at this time p.i. (data not shown).
The lungs of mice infected with MHV76-K1 were immuno-
stained for expression of the K1 protein with an antibody that
recognized a Myc epitope at the C terminus, but the protein
was found to be below the level of detection of this technique
(data not shown).
Long-term infected mice. Groups of four BALB/c mice were
infected with MHV-76, MHV76-GFP, or MHV76-K1 and sac-
rificed on day 120 p.i. Their organs (lungs, livers, spleens,
kidneys, and blood) were removed for histopathological exam-
ination and an analysis of viral antigen expression. The livers of
MHV76-K1-infected mice showed focal mixed zone 1 vasculi-
tis/perivasculitis compared with a mild chronic periportal in-
flammation in mice infected with MHV-76 or MHV76-GFP
(data not shown). No abnormalities were detected in the kid-
neys or spleens of infected mice (data not shown). An in-
creased inflammatory response was observed in the lungs of
MHV76-K1-infected mice at day 120 p.i. compared with those
of both MHV-76- and MHV76-GFP-infected mice (data not
shown).
One of four mice infected with MHV76-K1 developed a
salivary gland adenocarcinoma at day 120 p.i. (Fig. 6A). Im-
munostaining of the tumor with polyclonal anti-MHV-68 sera
confirmed the presence of the virus (Fig. 6B). The tumor was
also immunostained for expression of the K1 protein with an
antibody that recognized a Myc epitope at the C terminus, but
again the protein was found to be below the level of detection
of this technique (data not shown).
Expression of K1 in MHV76-K1-infected mice. Although
immunostaining of tissue sections for the expression of K1
proved negative, we were able to show the expression of K1 in
MHV76-K1-infected mice by immunoprecipitation with a
monoclonal antibody against the Myc epitope tag. The West-
ern blot in Fig. 7 shows the presence of a 50-kDa protein in cell
lysates from both the lung (day 5 p.i.) and salivary gland ade-
nocarcinoma. The migration of this protein species was con-
FIG. 4. (A) Viral replication in lungs of BALB/c mice infected intranasally with 4  105 PFU of MHV-76 (black bars), MHV76-GFP (gray
bars), or MHV76-K1 (white bars). The mean log10 virus titer 	 standard error for four mice per group is shown for each time point. MHV76-GFP
had a significantly lower titer than MHV-76 or MHV76-K1 on day 5 p.i. (P  0.01). (B) Numbers of spleen cells during intranasal infection of
BALB/c mice with 4  105 PFU of MHV-76 (), MHV76-GFP (‚), or MHV76-K1 (E). The mean total number of splenocytes 	 standard error
for four mice per group is shown for each time point. MHV76-K1-infected mice had a significantly higher splenocyte number than MHV76-GFP-
or MHV-76-infected mice on day 14 p.i. (P 0.05). (C) Latent virus in spleens of BALB/c mice infected intranasally with 4 105 PFU of MHV-76
(black bars), MHV76-GFP (gray bars), or MHV76-K1 (white bars), as determined by an infective-center assay. The mean number of infective
centers per spleen 	 standard error for four mice per group is shown for each time point. MHV76-K1 had a significantly higher latent viral load
than MHV76-GFP on day 10 p.i. (P  0.001).
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sistent with the predicted molecular mass of the glycosylated
K1 protein (14).
DISCUSSION
Investigations of the mechanisms through which KSHV is
involved in tumorigenesis are hampered by the lack of useful
animal model systems. We have made use of the well-charac-
terized murine gammaherpesvirus MHV-76 to generate re-
combinants expressing both EGFP and the KSHV ORF K1.
MHV-76 is a naturally occurring deletion variant which, simi-
lar to MHV-68, grows to high titers and forms plaques in
monolayer cell cultures, thus facilitating the generation of virus
recombinants (6, 17). The recombinant viruses were generated
by homologous recombination at the left end of the unique
portion of the MHV-76 genome and resulted in the insertion
of a CMV-IE promoter expressing a bicistronic transcript. This
transcript encoded EGFP, an IRES element, and the K1 gene.
Recombinant viruses could be identified by virtue of their
expression of EGFP, and the K1 gene was expressed through
the IRES. The in vitro growth kinetics of viruses expressing
EGFP alone (MHV76-GFP) or EGFP and K1 (MHV76-K1)
were compared with those of MHV-76 and were found to be
similar. However, after the infection of BALB/c mice by the
intranasal route, we observed a 10-fold increase in the titer of
MHV76-K1 compared with that of MHV76-GFP in the lungs.
A histological examination of lung sections revealed a minor
hyperproliferative response of the lung epithelial cells in re-
sponse to the MHV76-K1 infection which appeared to be
quantitatively different but qualitatively similar to that in re-
sponse to MHV-76 infection. It is possible that this was due to
the transient expression of the K1 gene promoting a prolifer-
ative response in the infected cell; however, further studies
would be required to investigate this hypothesis further. One
function of K1 during KSHV infection might therefore be to
induce cellular proliferation and increase the pool of infected
cells, which would be reflected in the increased titers observed
in the lungs. Alternatively, it has been demonstrated that
ITAM-dependent signaling by K1 can act to augment lytic
reactivation in KSHV-infected B cells (13). The enhancement
of lytic replication of the MHV76-K1 recombinant virus by K1
expression would also result in the observed increase in lung
titers.
The increased replication of MHV76-K1 in the lungs (com-
pared with MHV76-GFP) was not reflected in the number of
latently infected cells in the spleen. The latent virus load
peaked at day 10 p.i. but was found to be 10-fold lower for mice
FIG. 5. (A) Hematoxylin and eosin staining of lung sections of mice infected with MHV-76, MHV76-GFP, or MHV76-K1 at days 5 and 10 p.i.,
showing perivascular inflammatory cell infiltrates (arrows). (B) Cytokeratin staining of lung sections of mice infected with MHV-76 or MHV76-K1
at day 10 p.i., showing strong staining of type 2 pneumocytes in chronic proliferative inflammatory foci (arrow). (C) Mice infected with MHV76-K1
express GFP in the lungs at day 5 p.i. MHV-76 antigens were stained with polyclonal antisera and an anti-rabbit tetramethyl rhodamine isocyanate
conjugate (red).
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infected with MHV76-K1 than for mice infected with MHV-
76. This may have been due to an increased immune response
to the EGFP or K1 gene product or possibly to interference of
the inserted DNA with latency determinants within the MHV-
76 genome. This region of the genome is known to be impor-
tant for the establishment of latency since MHV-76 has a
50-fold reduction in latent virus load compared with MHV-68
(17). Although the number of splenocytes that were latently
infected with MHV76-K1 was low, it was approximately three-
fold higher than that for MHV76-EGFP-infected mice on days
10 and 14 p.i. (P  0.001 on day 10 p.i.). We also observed a
small increase (two- to threefold) in the number of splenocytes
in mice infected with MHV76-K1 compared with that in mice
infected with MHV-76 or MHV76-GFP (P  0.05 on day
14 p.i.). Thus, as for productively infected cells, the function of
K1 during infection might be to induce cellular proliferation,
resulting in an expansion of the pool of infected B cells.
A salivary gland adenocarcinoma was observed in one of a
group of four mice infected with MHV76-K1 at day 120 p.i.
This is comparable with the low rate of tumor development (2
of 13 mice at 14 months) observed in transgenic mice express-
ing K1 under the control of the SV40 promoter (21A). Immu-
nostaining of sections of the tumor with polyclonal MHV-68
antisera revealed the presence of viral antigens. Although we
were unable to detect the expression of K1 in the tumor by
immunostaining, K1 expression in the tumor was confirmed by
immunoprecipitation and Western blot analysis (Fig. 7). Long-
term infection with MHV-68 can result in the formation of
lymphomas (26). However, we have never previously observed
salivary gland tumors developing in mice infected with MHV-
68 or MHV-76. These results suggest that K1 is a contributing
factor in KSHV-induced tumors. Lee et al. (16) have reported
the construction of a recombinant HVS in which STP was
replaced with KSHV K1. This virus was shown to induce T-cell
lymphomas in two of two common marmosets. Although the
level of tumor induction in mice infected with MHV76-K1 was
lower, this may reflect the lower natural tumorigenic potential
of MHV-76 than that of HVS. A small proportion of mice
infected with MHV-68 for 
12 months or in the context of
immunosuppression have been observed to develop B-cell lym-
phomas (26). Since HVS is an inherently more tumorigenic
virus, we cannot discount the contribution of other viral genes
to the tumor development observed with the HVS-K1 recom-
binant.
In conclusion, we have presented the development of a
small-animal model for the study of the pathogenicity of
KSHV-encoded gene products. The infection of mice with
recombinant MHV-76 expressing KSHV K1 induced a tran-
sient hyperproliferation of lung epithelial cells and a salivary
gland tumor in one of four infected mice.
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